AstraZeneca Results Presentation Deck
BioPharmaceuticals: new launch medicines
Portfolio of new medicines across uses and markets
Europe $63m (+25%);
Japan $26m (+19%)
US, total patient share
Leading new biologic
medicine in many markets¹
US $156m (+30%)
Leading novel biologic¹
100%
80%
60%
Fasenra
Severe asthma
40%
20%
0%
Q4 2017
Q2 201
SQ4 2018
tan Q2 2019
Q4 2019
Con Q2 2020
52%
48%
etit Q4 2020
Total revenue at actual exchange rates. 1. Market shares are
total patient share in severe, uncontrolled asthma; specialty
pharmacies and 'buy and bill' market, IQVIA market research.
17
Breztri
COPD
US $12m
Achieved 20%+ share of
new patients²
EMs $9m
Continued launch in China;
NRDL inclusion in place.
Japan $5m
Achieved 25%+
share of new
patients²
2. IQVIA market research.
ストリエアロスフィア
ピレーズトリ
エアロスフィア
56双入
FASUDAAN
GHASKA
TS
$m
40
30
20
10
0
Lokelma
Hyperkalaemia
Global $33m; US $24m
US market leadership³;
COVID-19 reduced growth
Global launch continued
Q1 2019
Q2 2019
Q3 2019
Q4 2019
2020
Q1
Q2 2020
Q3 2020
Q4 2020
Q1 2021
T₁
US Europe EROW EMS
Total revenue at actual exchange rates. 3. Market leadership in
both total and new-to-medicine patients, IQVIA market research.
$m
50
40
30
10
20-
0
EMs $41m
Now recording sales in
China. Increased hospital
listings and patients
roxadustat
Anaemia in CKD
US
Regulatory decision H2 '21
Q1 2020
Q2 2020
Q3 2020
Q4 2020
EMS
Total revenue at actual exchange rates.
Q1 2021
3View entire presentation